Dirk Strickmann has more than 20 years of experience in the pharmaceutical industry/biotechnology (ABRI Vienna, Novartis/Sandoz & Nabriva Therapeutics GmbH) in various positions with a strong scientific background as a chemist and bioanalyst, covering all phases of drug development from initial synthesis through the various preclinical and clinical development phases to regulatory submissions. He can also look back on 7 years of experience as Managing Director of Nabriva Therapeutics GmbH.

The InnoFly BioCenter location at Leberstraße 20, 1110 Vienna, was significantly designed by Dirk Strickmann. In July 2024, Otto Kanzler handed over the management of InnoFly BioCenter to Dirk Strickmann.

Due to his extensive and decades of experience in process development and business development in the field of biotechnology, Otto Kanzler has become a sought-after and successful management consultant. Since 2007, he has been working as an independent management consultant for production and technology development in the biotechnology and pharmaceutical industries with a focus on strategic and economic issues.

Otto Kanzler is a co-founder, board member, CEO and/or CFO of several biotech companies in Austria. From 1993 to 2007, he was Head of Department at Boehringer Ingelheim Austria. He was responsible for the economic issues of the biopharmaceutical industry. Previously, he was Head of Process Development for Biopharmaceutical Processes at Boehringer Ingelheim Austria (1981 – 1993).

During his more than 25 years of experience in all areas of accounting, Erich Jaklitsch acquired profound and versatile technical know-how. After 10 years of working in various SMEs, he has been an independent accountant since 2001 and a self-employed accountant since 2009, specializing in service companies and innovative spin-offs.

Erich Jaklitsch is co-founder and CEO of InnoFly Management GmbH. In this role, he is responsible for the ongoing accounting, balancing and tax optimisation of our clients and acts at the interface with authorities and external partners.

Klaus Graumann brings more than 20 years of experience in the biopharmaceutical industry (Boehringer Ingelheim (Austria) and Novartis) and has been involved in the development of more than 10 now commercial biopharmaceuticals in various local and global leadership positions. Since mid-2018, he has been active as a start-up founder with a focus on stem cell technologies (Phoenestra GmbH) and as a management consultant in the field of biotechnology (CMC).